Landscape construction
1000+programs mapped
Map every stage
We covered development status, mechanism of action and positioning for programs across both diseases.
Case Study · Pipeline Landscape
Spotting the next assets in neurodegeneration.
A global biopharma company wanted to advance its pipeline in Alzheimer’s and Parkinson’s diseases. Prescouter mapped more than 1000 small-molecule programs and built a framework that flagged over 30 likely peri-IND programs worth a closer look.
The Client
The client is a global biopharma company. It wanted to explore strategic opportunities across neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases.
The Challenge
A crowded field.
Find the ready assets.
The client needed a comprehensive view of small-molecule assets across Alzheimer’s and Parkinson’s diseases, from discovery to approval, with a sharp focus on programs nearing an Investigational New Drug filing.
-
Scope
Discovery to approval
Every stage of development.
-
Readiness
Peri-IND focus
Programs nearing IND submission.
-
Deals
Acquisition targets
Assets to partner with or buy.
Our Approach
A full landscape and a readiness framework.
IND readiness system
3readiness categories
Score readiness
Preclinical programs were classed as likely peri-IND, adjacent to IND or exploratory assets.
Asset identification
30+likely peri-IND programs
Flag near-term assets
We found over 30 likely peri-IND programs beyond those already marked as IND-ready.
The Outcome
From 1000+ programs to a focused shortlist.
Prescouter delivered landscapes covering more than 1000 Alzheimer’s and Parkinson’s programs and identified over 30 likely peri-IND programs, those nearing IND submission within 18 months. It also highlighted potential strategic partners, equipping the client to optimize pipeline development and pursue external innovation.
-
Near term
Likely peri-IND assets
IND submission within 18 months.
-
Mid term
Adjacent to IND
IND readiness within 3 years.
-
Framework
A dynamic system
Adapts as priorities evolve.
In a crowded therapeutic area, timing matters as much as mechanism. A clear view of IND readiness shows which assets are worth a conversation now.
Let’s Talk
Which assets belong in your pipeline?
Map the programs across your therapeutic areas and spot the assets ready for partnership or acquisition. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]